Skip navigation

Niven R. Narain, Ph.D.

Chairman, President & CEO

Dr. Niven R. Narain is a recognized pioneer in technology development at the intersection of biology and AI. Niven developed the Interrogative Biology® platform that has unraveled actionable disease insight leading to both de novo and repurposed development of a robust pipeline of products in oncology, metabolic, rare, and CNS diseases, namely BPM 31510 currently in Phase 2 trials for cancer. These discoveries are covered by over 400 issued and pending US and international patents.

Dr. Narain is a member of the NASA/Gene Lab Steering Committee and Advisor to US Department of Defense (DoD) leadership on breast and prostate cancer. He has forged strategic partnerships with industry, academia, and US and UK governments. He serves on the Advisory Board of Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Healthy Aging Initiative Commission at No. 10 for the UK Prime Minister. He is an industry thought leader in precision medicine, drug development, and AI/ML. He serves as a frequent speaker at Economist, Bloomberg, Financial Times, Wired, and Aspen Ideas as well as many international meetings on medicine and technology.

In 2014, Dr. Narain was named to the Boston Business Journal top 40 leaders under 40; In 2018, he was an EY Entrepreneur of Year finalist; In 2019, he was named to the Deep Knowledge Analytics Top 100 AI Pioneers in Drug Discovery and Advanced Healthcare.

Dr. Narain obtained a BS in Biological Sciences/Philosophy from St. John’s University, NY and a Ph.D. in Clinical Biochemistry with focus on Cancer Biology at the University of Miami Miller School of Medicine where he also did clinical research training in Cutaneous Oncology in the Dermatology and Cutaneous Surgery School. He later served as Director of Cutaneous Oncology Research. He has published in high impact journals with collaborators from academia, NIH, and DoD. Dr. Narain is most passionate about improving patient care and enabling increased access to innovative medicines. He is very active in educational programs for STEM in Massachusetts.